



Unlocking Epigenetic Therapeutics to Revolutionize Medicine

September 2023



Disclaimer

This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable securities laws and regulations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements with respect to DURECT's plans to report topline data from the AHFIRM trial in Q4 2023, anticipated product benefits and other potential uses of larsucosterol, anticipated product markets and potential sales, clinical trial results and plans, DURECT's future business plans and projected financial results, DURECT's emergence as an innovative biopharmaceuticals company and other future events that involve risks and uncertainties. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the AHFIRM trial takes longer to complete than anticipated, the risk that ongoing and future clinical trials of larsucosterol do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner, the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving it for the treatment of alcohol-associated hepatitis even if the results of the AHFIRM trial are successful, and risks related to the sufficiency of our cash resources, our anticipated capital requirements and capital expenditures, our need or desire for additional financing, our ability to obtain capital to fund our operations and expenses and our ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent U.S. Securities and Exchange Commission ("SEC") filings, including its Annual and Quarterly Report on Form 10-K or 10-Q, respectively, filed with the SEC under the heading "Risk Factors." DURECT is under no duty to update any of these forward-looking statements after the date of this presentation to conform these statements to actual results or revised expectations, except as required by law. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Subsequent events and developments may cause DURECT's expectations and beliefs to change.

Certain data in this presentation are based on cross-study comparisons and are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities or differences.

This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. Any offer of securities will only be made pursuant to a registration statement (including a base prospectus) and prospectus supplement filed with the SEC, copies of which may be obtained for free on our website at www.durect.com under the "Investors" tab or by visiting EDGAR on the SEC website at www.sec.gov. All information provided in this presentation is based on information available to DURECT as of September 8, 2023, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.

Company Highlights



Harnessing the power of epigenetic modulation

Larsucosterol: Potential first-in-class treatment for AH

Potential pivotal trial ongoing; data expected in Q4 2023

Compelling Phase 2a data in AH

Significant unmet need in AH – no approved therapy

PIPELINE

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Marketed	Status
Epigenetic Modulator Program							
Larsucosterol	Alcohol-Associated Hepatitis (AH) (intravenous administration)	<div></div>					Enrollment completed in Phase 2b AHFIRM trial; topline data expected Q4 2023
	Non-Alcoholic Steatohepatitis (NASH) (oral administration)	<div></div>					Positive Phase 1b topline data
NCEs ¹	Hematology/Oncology (small molecules)	<div></div>					Molecule selection targeted for Q4 2023
Partnered Program							
POSIMIR® (bupivacaine solution)	Post-surgical pain ²	<div></div>					Sold by Innocoll in the U.S.; DURECT maintains ex-U.S. rights

¹ New chemical entities; ² Indicated for post-surgical analgesia for up to 72 hours following arthroscopic subacromial decompression

Larsucosterol Overview


Lead Compound in DURECT's Epigenetic Modulator Program

Modulator of DNA methylation

- New class of therapeutics
- Endogenous sulfated oxysterol
- Highly conserved across all 7 species studied to date

Role in cellular functions

- Stabilizes mitochondria
- Reduces lipotoxicity
- Regulates inflammatory or stress response
- Promotes cell survival



Larsucosterol
5-cholesten-3 β , 25-diol 3-sulfate (25HC3S)

Clinical safety

- Well tolerated at all doses
- More than 500 subjects dosed in multiple completed Phase 1 & 2 studies

Broad therapeutic potential

- MOA¹ supports investigating larsucosterol for the treatment of multiple acute organ injuries and chronic liver diseases
- Phase 1b NASH data suggest broad activity




Larsucosterol Potential in Alcohol-associated Hepatitis

What is Alcohol-associated Hepatitis?

- Life-threatening form of alcohol-associated liver disease (ALD)
- Can occur in individuals who chronically misuse alcohol— frequently after increased consumption
- Characterized by jaundice and severe inflammation – indicative of SIRS (Systemic Inflammatory Response Syndrome)
- SIRS causes a sepsis-like state that may progress to multi-organ failure and ultimately death

~26%
28-day
mortality rate¹


~30%
90-day
mortality rate¹



AH Imposes High Economic Burden on US Healthcare System

- ~158,000 U.S. hospitalizations in 2020¹
- Incidence may yield ~300K hospitalizations by 2034² based on historical rapid yearly growth rate of 5.5% between 2015-2019³
- Increased physician and hospital awareness of AH could result in more robust ICD-10 coding and increased recorded hospitalizations
- 86% of hospitalized AH patients are insured³

Each hospitalization episode with AH¹:



Current Treatments for AH are Inadequate with No Approved Therapies

Corticosteroids


- Used as first-line treatment despite limited and inconsistent survival benefits and widely acknowledged contraindications^{1,2,3}
- Only 25% to 45% of patients are eligible for corticosteroids^{4,5,6}

Stopping Alcohol Consumption

- Not sufficient in many patients⁷

Liver Transplant

- Becoming more common for AH⁸ but unavailable to most patients due to:^{3,9}
 - High liver transplant costs >\$875,000
 - Requirement of lifelong immunosuppression
 - Limited availability of donated organs



Larsucosterol could be the first drug approved for AH by the FDA and EMA

References:

¹Crabb DW et al. 2016. *Gastroenterology*, 150:785-790; ²Shipley LC and Singal AK. 2020. *Transl Gastroenterol Hepatol*, 5:26; ³Singal AK et al. 2018. *Am J Gastroenterol*, 113:175-194; ⁴Singal AK et al. 2018. *J Hepatol*, 69:534-543; ⁵Singal AK and Mathurin P. 2021. *JAMA*, 326:165-176; ⁶Bataller et al. 2022. *N Engl J Med*, 387:2436-2448; ⁷Singal AK et al. 2014. *Clin Gastroenterol Hepatol*, 12:555-564; ⁸Cotter TG et al. 2021. *Am J Transplant*, 21:1039-1055; ⁹Tornai D and Szabo G. 2020. *Clin Mol Hepatol*, 26:686-696; ¹⁰Thursz M et al. 2015. *NEJM*, 372: 1619-1628.

Physicians and Hospital Stakeholders need therapy that:

CAN REDUCE MORTALITY

Steroids have no significant effect on 90-day mortality

NOT SUBJECT TO PATIENT COMPLIANCE

Given low compliance and follow-up, issues with 28-day steroid courses are common;
An acute inpatient drug with short treatment course would be beneficial

ADDRESSES MILD/MODERATE AH

There would be a clinical benefit in catching these patients early in their disease trajectory, who currently have no options

PREVENTS ALCOHOL USE POST-DISCHARGE

30-40% of AH patients drink alcohol following discharge with low compliance with support programs

Larsucosterol Near-Term Opportunity

Larsucosterol Long-Term Opportunity



Larsucosterol

Phase 2a Trial in AH



Larsucosterol: Summary of Phase 2a Trial in AH^{1,2}

100% survival (19/19) at 28 days in open label Phase 2a trial in patients with moderate to severe AH

- Patients received up to two doses of larsucosterol on Day 1 and Day 4 (if still hospitalized)
 - Multiple dose levels studied: 30mg, 90mg and 150mg
- Showed improvement in key biomarkers and prognostic indicators
 - Reduction in bilirubin and Model for End-stage Liver Disease (MELD) scores
 - 89% response rate based on prognostic indicator of mortality (Lille score) - statistically better than those of well-matched patients from an Observational Arm and Study-Steroid Arm of the DASH Consortium trial in a cross-study comparison
- Well tolerated across all dose levels with no drug-related SAEs
- Oral late-breaking presentation delivered by Dr. Tarek Hassanein²
 - Selected for 'Best of The Liver Meeting' summary slide presentation in the alcohol-related liver disease category





Phase 2a: Majority of Patients Discharged After One Dose

Potential Pharmacoeconomic Benefit as Measured by Time to Discharge

Number (%) of patients who were discharged in <4 days after receiving a single dose of larsucosterol	
All patients (n=19)	14/19 (74%)
Severe patients (MELD 21-30) (n=12)	8/12 (67%)

Phase 2a: Reduction in Bilirubin & MELD

More Pronounced Effect in Patients with Higher Bilirubin





One of 19 patients did not return for the follow-up visits on Day 7 and Day 28; all data were analyzed based on those who completed visits.

Phase 2a: Lille Score Provides Strong Signal for Survival

Composite score that determines response to treatment and risk of death

Larsucosterol treatment resulted in 89% (16/18) response rate by Lille Score (< 0.45)



¹Louvet A et al. 2007. *Hepatology*, 45:1348-1354.


²n=18 ; one patient did not return for the day 7 visit.

Statistically-significant Reduction in Lille Score in Severe AH Patients

- Severe AH patients who received 30 or 90 mg of larsucosterol in Phase 2a (n=8) had lower Lille scores than patients from contemporaneous NIH-funded DASH study
 - Observational (n=8) and Study-Steroid arm (n=16) received standard-of-care, including corticosteroids
 - Comparator arm patients well-matched by MELD score to larsucosterol-treated patients

Arm	Median Baseline MELD
Observational	24.5
Larsucosterol	24.5
Study-Steroid	24.0

Well-matched severe AH patients in the two comparator arms




** Represents $p < 0.01$ by T-test

Larsucosterol Improved Liver Enzymes in Severe AH Patients

Statistically-significant reductions in ALT vs. comparison groups

Both ALT and AST enzymes decreased rapidly in severe AH patients in the 30 and 90 mg larsucosterol cohorts


Change in ALT from Baseline



** Represents p<0.01 by T-test

**** Represents p<0.0001 by T-test

Change in AST from Baseline



Phase 2a: Larsucosterol Was Well Tolerated Across All Doses

- No serious adverse events attributed to trial drug
- No discontinuations, early withdrawal or termination of trial drug or trial participation due to larsucosterol-related adverse events
- Adverse events possibly related to larsucosterol:
 - 1 occurrence each of moderate generalized pruritus, mild rash, & grade 2 ALP



Larsucosterol AHFIRM Trial

Phase 2b Trial in **A**lcohol-associated
Hepatitis to Evaluate Sa**F**ety and
Eff**I**cacy of La**R**sucosterol Treat**M**ent



Larsucosterol: Potential to be First Approved Therapy for AH

Positive Phase 2a Data Led to Ongoing Phase 2b AHFIRM Trial



- AHFIRM: Phase 2b double-blind, placebo-controlled, multi-center, international efficacy trial in severe AH patients (n=301)
 - Completed enrollment in Q2 2023; topline data expected in Q4 2023
 - Primary endpoint is reduction in mortality or liver transplant at 90 days
- Potential NDA filing subject to achievement of primary endpoint
 - 65% of new drugs approved in the U.S. in 2020 were approved based on single pivotal trial¹
 - Previously granted Fast Track Designation


AHFIRM Trial Design Leverages Lessons from Phase 2a Trial

Aim: Demonstrate Safety and Efficacy in Severe AH

Key
Inclusion
Criteria

- **Severe AH patients** with MDF¹ score ≥ 32 and MELD score 21-30
- **301 subjects** randomized to three groups in a 1:1:1 ratio

Study
Design²



¹ Maddrey's Discriminant Function


² All patients receive supportive care, which for placebo patients may include methylprednisolone capsules at the investigators' discretion. In order to maintain blinding, patients in the two larsucosterol arms receive matching placebo capsules if the investigator prescribes steroids.

Physicians are enthusiastic about larsucosterol, given:

MECHANISM OF ACTION (MOA)

High enthusiasm for novel, specific MOA which targets the underlying liver inflammation and degradation



 Level of enthusiasm

CLINICAL EFFICACY

Reduction in 90-day mortality viewed as advance, as steroids do not show an effect on mortality past 28 days



SAFETY AND TOLERABILITY

Larsucosterol safety profile was well-received, with hundreds of patients dosed viewed as compelling for use



DOSING AND ADMINISTRATION

Physicians saw no issues with inpatient IV doses



Distinct value drivers across stakeholders highlight importance of tailored framing of larsucosterol value proposition

Larsucosterol has the potential to become a >\$1B/yr drug in the U.S. for the AH indication alone

Reduction in Mortality

Physicians prioritize **mortality** as the **most important endpoint**, and nearly all found a potentially significant reduction in **90-day mortality** or **liver transplant** rate clinically meaningful

Hospital Cost Offset Economics

Reducing costly **length of inpatient stays** and **30-day readmissions** is key for offsetting drug costs and securing favorable hospital formulary inclusion

Reduction in Healthcare System Cost Burden

Hospital economics and payer stakeholders may use **reduction in 30-day readmissions** to assess impact on per-patient cost burden, while **reduction in AH liver transplants** supports cost-benefit to the overall healthcare system

Shaping the AH Market

Educate on the impact of epigenetic dysregulation and larsucosterol's potential value

AH AND EPIGENETICS WEBSITE LAUNCH



- **GOAL:** Raise awareness of AH unmet needs and increase understanding of epigenetic regulation as a potential link to AH
- **TARGET AUDIENCE:** US HCPs (primarily: hepatologists, GIs; secondarily: ER physicians, hospitalists, and advance practice providers.
- **Domain name:** <https://www.exploreAHepigenetics.com/>

KOL ENGAGEMENT



Growing medical team engaging with KOLs at key conferences and through long-term physician personal relationships



Financial Overview and Summary

Financial Overview

Cupertino, CA headquarters

Nasdaq	DRRX
Market Cap	\$84.5 MM ¹
Shares O/S	27.6 MM ²
Cash & Cash Equivalents	\$48.7 MM ³
Debt	\$20.7 MM ⁴
Federal NOLs	\$317.7 MM ⁵



¹ As of August 31, 2023

² As of August 7, 2023

³ As of June 30, 2023. Pro forma for receipt of \$13.8M of net proceeds from July 2023 registered direct offering.

⁴ As of June 30, 2023

⁵ As of December 31, 2022



Larsucosterol – Positioned for Success in AH

Robust Phase 2b Trial w/ Registration Potential

- Global, randomized, double-blind, placebo-controlled efficacy trial
- 301 patient, 3 arm trial
- Clearly-defined patient population
- Straightforward endpoint
- Well positioned to show potential clinical benefit
- Fast Track Designation

Clinical Efficacy Demonstrated in Phase 2a Trial

- 100% 28-day survival
 - 26% historical mortality rate at 28 days¹
- 74% of patients discharged in < 4 days after 1 dose
- 67% of severe patients discharged in < 4 days after 1 dose

Clinical Safety

- Well tolerated
- No discontinuations
- More than 500 patients dosed in multiple Phase 1 & 2 trials
- Multiple dose levels studied (30mg, 90mg, 150mg)

Clinically Relevant Mechanism of Action




- Upregulation of DNMTs differentiates AH from other liver diseases
- Larsucosterol inhibits DNMT activity
- Protective against multi-organ failure in multiple nonclinical models

Topline data from AHFIRM Phase 2b trial expected in Q4 2023






Appendix

Inhibition of DNMT-1, 3a & 3b Aligns with AH

Liver samples from patients with severe AH have increased expression of DNMT-1 & 3a



Larsucosterol AH Launch; Strategic Imperatives (SI)

SI1	SI2	SI3	SI4	SI5
				
Shape the AH Market	Build the Brand	Define Patient Access	Drive Rapid Adoption	Maximize Long-Term Value

Large Alcohol Use Outside of the U.S. Calls for New Treatments

GERMANY

“Harmful alcohol consumption in Germany is a serious public health problem: About 7.7 million adults in Germany can be classified as risky alcohol consumers, about 74,000 deaths per year are related to alcohol consumption, and about 1.8 million adults in Germany (18–64 years) are classified as alcohol dependent.” — Hoffmann et al. 2019. *BMC Fam Pract*, 20, 115.

FRANCE

“Almost 10% of French adults drink daily, 5% report binge drinking at least once a week, and 3.8% (approximately 2 million people) report regular alcohol intoxication” - Costa et al. 2022. *BMC Public Health*, 20: 358.

ENGLAND

Almost 980,000 admissions to hospital in 2019/2020 were linked to alcohol-liver disease; this represents 5.7% of all hospital admissions in England - NHS Digital ‘Statistics on Alcohol, England 2021’ Publication date: 27.01.22

We estimate that the NHS in England spends a total of around £45 million per year on caring for patients with AH.” — Turner et al. EASL 2023

SPAIN

“Admissions due to AH have increased recently, potentially related to COVID. Access to liver transplant is very limited (<2%), mainly due to contraindications, social, addiction-related, or medical comorbidities.”

- Garcia et al. EASL 2023

ASIA

“The overall prevalence of ALD is 4.8%; ALD prevalence in Asia increased over the past two decades, calling for the implementation of specific actions to invert this trend.” — Sun et al. 2022. *Liver International*, 42: 1926-1929.

AUSTRALIA

“Alcohol use contributed to 4.5% of the total burden of disease in Australia in 2018.” — Australian Institute of Health and Welfare: <https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia/contents/impacts/health-impacts> - Accessed June 2023.